Welcome to our dedicated page for 20/20 Biolabs news (Ticker: AIDX), a resource for investors and traders seeking the latest updates and insights on 20/20 Biolabs stock.
20/20 BioLabs news covers the commercialization of its OneTest laboratory blood-test families, including OneTest for Cancer and OneTest for Longevity. Recurring developments include cancer screening programs, practitioner-channel distribution, AI-enabled chronic disease risk assessment, biomarker technology updates, and laboratory operations tied to its CAP-accredited and CLIA-licensed facility.
Company updates also report financial results, Nasdaq public-company milestones, material license or collaboration agreements, and customer-market activity in public-sector, occupational health, functional medicine, and direct-to-consumer channels.
20/20 Biolabs (Nasdaq:AIDX) announced contingency planning to add Ebola and Hantavirus PCR testing in its CAP-accredited CLIA lab if public health labs face overflow demand. The company will leverage prior COVID-19 testing experience, when it processed over 400,000 samples during 2021–2022.
The company is assessing global PCR kit suppliers and repurposing existing equipment to expedite assay validation if needed. The announcement does not indicate current regulatory authorization, clinical availability, or a decision to commercialize these tests.
20/20 BioLabs (Nasdaq:AIDX) reported Q1 2026 revenue of $0.4 million, down from $0.6 million in Q1 2025, with gross margin of 17.8% and net loss of $2.2 million.
Cash rose to $4.2 million after a $5.0 million private placement. State-funded firefighter cancer screening programs, new licensing and distribution agreements, and the launch of OneTest™ for Longevity are expected to drive revenue growth from Q2 2026. The company listed on Nasdaq on February 19, 2026, and holds a preferred equity facility of up to $40.0 million, subject to conditions.
20/20 BioLabs (Nasdaq:AIDX) will attend the Sidoti Micro-Cap Virtual Conference on May 20, 2026. CEO Jonathan Cohen will host a presentation from 3:15 PM to 3:45 PM ET in Track 1 and participate in one-on-one investor meetings.
Topics include recently reported quarterly results, recent partnership and licensing activity, and plans to scale the OneTest platform. Investors can access the webcast and schedule meetings through the conference website or conference representatives.
20/20 BioLabs (Nasdaq:AIDX) signed an exclusive worldwide license with the University of South Carolina for a patented PSA velocity algorithm that tracks changes in prostate-specific antigen over time to help flag potentially aggressive prostate tumors earlier.
20/20 plans to integrate the technology into its AI-enabled OneTest for Cancer platform and offer it to other laboratories via software-as-a-service. The partners also anticipate joint research on similar velocity algorithms for markers such as CA 125 and CA 19.9.
20/20 BioLabs (Nasdaq: AIDX) announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, effective April 7, 2026. The collaboration gives OneTest broader visibility across Evexia’s network of ~40,000 functional and integrative medicine practitioners to support adoption and clinical access.
The partnership aims to simplify ordering and integration into clinical workflows while enabling practitioners to use OneTest’s biomarker quantification for baseline and longitudinal patient monitoring.
20/20 BioLabs (Nasdaq: AIDX) reported FY2025 revenue of $2.0 million, up 17% year-over-year, with gross profit $0.6M (+68%) and gross margin expanding 900 basis points to 29.6%. Operating expenses fell 35% to $3.9M and net loss improved to ($3.7M).
The company completed a $5.0M private placement on February 19, 2026, secured $520,000 in Maryland state funding for firefighter screenings, launched OneTest for Longevity with IBM AI support, licensed ROKIT CKD technology, and began Nasdaq trading under AIDX.
20/20 BioLabs (Nasdaq: AIDX) announced that 18 Maryland fire department groups will receive over $520,000 from the Maryland Department of Health to fund its OneTest™ multi-cancer early detection blood test.
Testing of an estimated 1,400+ firefighters is expected in April–May 2026, a ~225% increase in funded MCEDs versus last year.
20/20 BioLabs (Nasdaq: AIDX) entered an exclusive U.S. license and access agreement with ROKIT Healthcare to integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into 20/20’s Longevity Platform, adding CKD risk assessment to its OneTest for Longevity offering.
Under the deal, ROKIT will reimburse one-third of mutually agreed sales and marketing expenses and receive a running royalty on net sales; the parties also anticipate negotiating separate exclusive commercialization rights for Korea and possibly other East Asian markets. The integration targets earlier CKD detection and enhanced biomarker-driven decision support for patients and providers.
20/20 BioLabs (Nasdaq: AIDX) outlines advantages of its patented protein tumor marker (PTM) approach for multi-cancer early detection, citing May–Nov 2025 validation studies showing up to 50% sensitivity for some early-stage tumors and a blinded MD Anderson study reporting ~90% early-stage lung cancer detection.
The company advocates a tiered screening model using protein-based OneTest first, then ctDNA or imaging, and notes a Feb 2026 Medicare coverage pathway beginning in 2028.
20/20 BioLabs (Nasdaq: AIDX) launched OneTest for Longevity, a commercial blood-test solution available Feb 25, 2026 that combines inflammatory biomarkers, dietary and lifestyle inputs, and curated research to estimate chronic disease risk and offer personalized dietary guidance.
The platform uses IBM watsonx.ai and IBM Granite 4.0 foundation models, with Docling reportedly processing nutritional research 30x faster. The test is offered as a laboratory-developed test (LDT) in CLIA-licensed, CAP-accredited labs and has not sought or received FDA approval.